Cancer is an uncontrolled expansion of atypical cells in the body. These unusual cells are labelled as cancerous or malignant cells. Melphalan, an anticancer drug which is imperatively recognized under the class of alkylating agents. It exhibits broad spectrum antitumor activity, as observed in ovarian cancer, breast cancer, etc. However, it is mainly utilized in the management of multiple myeloma. Several studies across the globe suggest that resistance to melphalan is the major concern that leads to relapsed myeloma. In the present paper, several pivotal approaches to compensate resistance associated with melphalan have been discussed. Numerous chemical and formulation developments concerning melphalan to enhance its salient characteristics and targeted profile have also been portrayed. The rationale of the current article also summarizes the recent analytical methods, structure-activity relationship, pharmacokinetics, interactions, potential adverse effects along with medicinal updates of melphalan. Special attention is also laid on their synthetic developments viz. melphalan derivatives, conjugates and prodrugs along with encouraging insights and research findings.

癌症是体内非典型细胞的不受控制的扩张。这些不寻常的细胞被标记为癌细胞或恶性细胞。美法仑，一种抗癌药物，在烷化剂类别中得到公认。它表现出广谱抗肿瘤活性，如在卵巢癌、乳腺癌等中观察到的那样。然而，它主要用于治疗多发性骨髓瘤。全球的几项研究表明，对美法仑的耐药性是导致骨髓瘤复发的主要问题。在本文中，讨论了补偿与美法仑相关的阻力的几种关键方法。还描述了许多关于美法仑的化学和配方开发，以增强其显着特性和目标特征。本文的基本原理还总结了最近的分析方法、构效关系、药代动力学、相互作用、潜在的副作用以及美法仑的药物更新。还特别关注它们的合成发展即。美法仑衍生物、偶联物和前药以及令人鼓舞的见解和研究成果。